The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies. As a SUMO E3 ligase, RANBP2 plays a pivotal role in post-translational modification, specifically SUMOylation, which is essential for regulating the cell cycle. Recent insights have highlighted the multifaceted involvement of RANBP2 in tumorigenesis, suggesting its potential as a therapeutic target for cancer treatment.

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs). As these diseases continue to impose a significant global health burden, the innovative use of mitochondrial gene editing offers a promising avenue to address their underlying causes. The dysfunction of mitochondria, triggered by mutations in mtDNA, is now recognized as a pivotal factor contributing to the development of several debilitating conditions, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS).

The interaction between RNA-binding proteins (RBPs) and circular RNAs (circRNAs) has emerged as a key area of interest in understanding cancer biology. As critical regulators of gene expression, RBPs control the formation and function of circRNAs, influencing various cancer-related processes such as tumor proliferation, metastasis, drug resistance, and immune evasion. This dynamic interplay has positioned the circRNA-RBP network as a promising target for developing innovative cancer therapies.